Oxidative metabolism of dopamine: A colour reaction from human midbrain analysed by mass spectrometry

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1784, Issue 11, 2008, Pages 1687-1693

  De Iuliis, Angela ^a   Arrigoni, Giorgio ^b   Andersson, Liselotte ^b   Zambenedetti, Pamela ^c   Burlina, Alessandro ^d   James, Peter ^b   Arslan, Paola ^a   Vianello, Fabio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b LUND UNIVERSITY   (Sweden)

^c Pathology Division and Brain Bank   (Italy)

^d San Bassiano Hospital   (Italy)

Author keywords

Dopamine; Dopamine peroxidizing activity; Dopaminochrome; Human brain; Mass spectrometry; Parkinson's disease

Indexed keywords

ANAZOLENE SODIUM; DOPAMINE; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE;

AEROBIC METABOLISM; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; FEMALE; GEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MASS SPECTROMETRY; MESENCEPHALON; OXIDATION; OXIDATION REDUCTION REACTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM; STAINING; TISSUE HOMOGENATE;

AGED; AGED, 80 AND OVER; COLOR; DOPAMINE; FEMALE; HUMANS; HYDROGEN PEROXIDE; MALE; MASS SPECTROMETRY; MESENCEPHALON; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; PEROXIDASE; PROTEINS; STAINING AND LABELING; SUBSTRATE SPECIFICITY;

ARMORACIA RUSTICANA; PARKINSONIA;

EID: 54049089936     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2008.07.002     Document Type: Article

References (82)

1. Greenamyre J.T., and Hastings T.G. Parkinson's-divergent causes, convergent mechanisms. Science 304 (2004) 1120-1122
2. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (2003) S26-S38
3. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and citotoxic quinone. Mol. Pharmacol. 14 (1978) 633-643
4. Graham D.G., Tiffany S.M., Bell W.R., and Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compound toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14 (1978) 644-653
5. Zecca L., Tampellini D., Gerlach M., Riederer P., Fariello G.R., and Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. J. Clin. Pathol. Mol. Pathol. 54 (2001) 414-418
6. Halliwell B., and Gutteridge J.M.C. Oxygen toxicity, oxygen radicals, transition metals and disease. J. Biochem. 219 (1984) 1-14
7. 2 oxidation of dopamine. J. Med. Chem. 38 (1995) 917-922
8. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64 (1995) 912-924
9. Mattamal M., Strong R., Lakshmi V.M., Chung H.D., and Stephenson A.H. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J. Neurochem. 64 (1995) 1645-1653
10. 3 and oxidation of dopamine to aminochrome. Biochem. Mol. Med. 58 (1996) 122-129
11. Foppoli C., Coccia R., Cini C., and Rosei A.M. Catecholamine oxidation by xanthine oxidase. Biochim. Biophys. Acta. 1334 (1997) 200-206
12. Bindoli A., Rigobello M.P., and Deeble D. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med. 13 (1992) 391-405
13. Ito S., Kato T., and Fujita K. Covalent binding of catechols to proteins through the sulphydryl group. Biochem. Pharmacol. 37 (1988) 1707-1710
14. Tse C.S., Mc Creery R.L., and Adams R.N. Potential oxidative pathways of brain catecholamines. J. Med. Chem. 19 (1976) 37-40
15. Zhang F., and Dryhurst G. Effects of l-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 37 (1994) 1084-1098
16. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. 93 (1996) 1956-1961
17. La Voje M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of metamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19 (1999) 1484-1491
18. Fornstedt B., Rosengren E., and Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, DOPA and DOPAC in the brain of eight mammalian species. Neuropharmacology 25 (1986) 451-454
19. Fornstedt B., and Carlsson A. A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J. Neural. Transm. 76 (1989) 155-161
20. Fornstedt B., Bergh I., Rosengren E., and Carlsson A. An improved HPLC-electrochemical detection method for measuring brain levels of 5-cysteinyldopamine, 5-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid. J. Neurochem. 54 (1990) 578-586
21. Fornstedt B., Pileblad E., and Carlsson A. In vivo autoxidation of dopamine in guinea pig striatum increases with age. J. Neurochem. 55 (1990) 655-659
22. Fornstedt B., and Carlsson A. Vitamin C deficiency facilitates 5-S-cysteinyldopamine formation in guinea pig striatum. J. Neurochem. 56 (1991) 407-414
23. Heacock R.A., and Powell W.S. Adrenochrome and related compounds. In: Ellis G.P., and West G.B. (Eds). Progress in Medicinal Chemistry vol. 9 (1973) 275-339 Amsterdam
24. Carstam R., Brinck C., Hindemith-Augustsson A., Rorsman H., and Rosengren E. The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta. 1097 (1991) 152-160
25. Odh G., Carstam R., Paulson J., Wittbejer A., Rosengren E., and Rorsman H. Neuromelanin of the human substantia nigra: a mixed-type melanin. J. Neurochem. 62 (1994) 2030-2036
26. Smythies J. On the function of neuromelanin. Proc. R. Soc. Lond. B 263 (1996) 487-489
27. Daveau C., Servy C., Dendane M., Marin P., and Ducrocq C. Oxidation and nitration of catecholamines by nitrogen oxides derived from nitric oxide. Nitric Oxide 3 (2002) 234-243
28. Rettori D., Tang Y., Dias Jr. L.C., and Cadenas E. Pathways of dopamine oxidation mediated by nitric oxide. Free Rad. Biol. Med. 33 (2002) 685-890
29. Galzigna L., De Iuliis A., and Zanetta L. Enzymatic dopamine peroxidation in substantia nigra of human brain. Clin. Chim. Acta. 300 (2000) 131-138
30. Galzigna L., Schiappelli M.P., Rigo A., and Scarpa M. A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine. Biochim. Biophys. Acta 1427 (1999) 329-336
31. De Iuliis A., Burlina A.P., Boschetto R., Zambenedetti P., Arslan P., and Galzigna L. Increased dopamine peroxidation in post-mortem Parkinsonian brain. Biochim. Biophys. Acta. 1573 (2002) 63-67
32. Chrambach A., Reisfeld R.A., Wyckoff M., and Zaccari J. A procedure for rapid and sensitive staining of protein fractionated by polyacrylamide gel electrophoresis. Anal. Biochem. 20 (1967) 154-164
33. Gorton J.E., and Jameson R.F. Complexes of doubly chelating ligands. I. Proton and copper-(II) complexes of l-β-(3,4-dihydroxyphenyl)alanine (DOPA). J. Chem. Soc. A (1968) 2615-2618
34. Mazur A., Green S., and Shoor E. The oxidation of adrenaline by ferritin iron and hydrogen peroxide. J. Biol. Chem. 213 (1956) 227-235
35. Bennett V., Gardner K., and Steiner J.P. Brain adducin: a protein kinase C substrate that may mediate site-directed assembly at the spectrin-actin junction. J. Biol. Chem. 263 (1988) 5860-5869
36. Ang S.-L. Transcriptional control of midbrain dopaminergic neuron development. Development 133 (2006) 3499-3506
37. Smith D.K., and Xue H. Sequence profiles of immunoglobulin and immunoglobulin-like domains. Mol. Biol. 274 (1997) 530-545
38. Lin C.-L., Chen H.-J., and Hou W.-C. Activity staining of glutathione peroxidase after electrophoresis on native and sodium dodecyl sulphate polyacrylamide gels. Electrophoresis 23 (2002) 513-516
39. Lee M.-H., Chuang M.-T., and Hou W.-C. Activity staining of plasma amine oxidase after polyacrylamide gel electrophoresis and its application to natural inhibitor screening. Electrophoresis 23 (2002) 2369-2372
40. Nellaiappan K., and Valivittan K. Differentiation of tyrosine hydroxylase and phenol oxidase after electrophoresis. Biotech. Histochem. 68 (1993) 281-283
41. Nellaiappan K., Nicklas G., and Sugumaran M. Detection of dopachrome isomerase activity on gels. Anal. Biochem. 220 (1994) 122-128
42. Nicklas G., and Sugumaran M. Detection of dopachrome isomerase on gels and membranes. Anal. Biochem. 230 (1995) 248-253
43. Valivittan K. A method for detecting dopaminechrome isomerase activity on gels. Biotech. Histochem. 74 (1999) 213-218
44. Schmidt M.L., and Trojanowski J.Q. Enzymatic detection of native and derivatized horseradish peroxidase in sodium dodecyl sulphate polyacrylamide gels. Anal. Biochem. 155 (1986) 371-375
45. Kho C.-W., et al. Activity staining of glutathione peroxidase after two-dimensional gel electrophoresis. Mol. Cells 18 (2004) 369-373
46. Shimazaki Y., Sugawara Y., Ohtsuka Y., and Manabe T. Analysis of the activity and identification of enzymes after separation of cytosol proteins in mouse liver by microscale nondenaturing two-dimensional electrophoresis. Proteomics 3 (2003) 2002-2007
47. Shimazaki Y., Hiraka Y., Uesugi Y., and Manabe T. Simultaneous analysis of esterase and transferase activities in cytosol proteins from the bovine retina by using microscale non-denaturing two-dimensional electrophoresis. Biochim. Biophys. Acta. 1696 (2004) 51-57
48. Thiele M., and Bernhagen J. Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid. Redox. Signal 7 (2005) 1234-1248
49. Odh G., Hindemith A., Rosengren A.M., Rosengren E., and Rorsman H. Isolation of a new tautomerase monitored by the conversion of d-dopachrome to 5,6-dihydroxyindole. Biochem. Biophys. Res. Commun. 197 (1993) 619-624
50. Rosengren E., Bucala E., Aman P., Jacobsson L., Odh G., Metz C.N., and Rorsman H. The immunoregulatory mediator macrophage inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 1 (1996) 143-149
51. Matsunaga J., Sinha D., Solano F., Santis C., Wistow G., and Hearing V. Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J. Biochem. 274 (1999) 3268-3271
52. Matsunaga J., Sinha D., Solano F., Santis C., Wistow G., and Hearing V. Macrophage migration inhibitory factor (MIF)-its role in catecholamine metabolism. Cell. Mol. Biol. 45 (1999) 1035-1040
53. Lashuel H.A., Aljabari B., Sigurdsson E.M., Metz C.N., Leng L., Callaway D.J.E., and Bucala R. Amyloid fibril formation by macrophage inhibitory factor. Biochem. Biophys. Res. Commun. 338 (2005) 973-980
54. Norris E.H., Giasson L.B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., and Lee V.M.-Y. Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280 (2005) 21212-21219
55. Rhee S.G., Chae H.Z., and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanism and emerging concepts in cell signalling. Free Rad. Biol. Med. 12 (2005) 1543-1552
56. Jung H., Kim T., Chae H.Z., Kim K.-T., and Ha H. Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J. Biol. Chem. 276 (2001) 15504-15510
57. Connor J.R., Menzies S.L., Burdo J.R., and Boyer P.J. Iron and iron management proteins in neurobiology. Pediatr. Neurol. 23 (2001) 118-129
58. Double L.K., et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66 (2003) 489-494
59. Chen Q., Beard J.L., and Jones B.C. Abnormal brain monoamine metabolism in iron deficiency anemia. J. Nutr. Biochem. 6 (1995) 486-493
60. Zecca L., Youdim M.B.H., Riederer P., Connor J.R., and Crichton R.R. Iron, brain aging and neurodegenerative disorders. Nat. Rev. 5 (2004) 863-873
61. Doulble K.L., Gerlack M., Youdim M.H., and Riederer P. Impaired iron homeostasis in Parkinson's disease. J. Neural Transm. 60 (2000) 37-58
62. Galazka-Friedman J., Bauminger E.R., Koziorowski D., and Friedman A. Mossbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra. Biochim. Biophys. Acta. 1668 (2004) 130-136
63. Smith M.P., and Cass W.A. GDNF reduces oxidative stress in 6-hydroxydopamine model of Parkinson's disease. Neurosci. Lett. 412 (2007) 259-263
64. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., and Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 4 (2004) 3943-3952
65. De Iuliis A., Grigoletto J., Recchia A., Giusti P., and Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin. Chim. Acta. 357 (2005) 202-209
66. Castegna A., Aksenov M., Thongbookerd V., Klein J.B., Pierce W.M., Booze R., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 82 (2002) 1524-1532
67. Mattson M.P., Pedersen W.A., Wenzhen D., Culmsee C., and Camandola S. Cellular and molecular mechanism underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann. N.Y. Sci. 893 (1999) 154-175
68. Berding G., Odin P., Brooks D.J., Nikkhah G., Matthies C., Peschel T., et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov. Disord. 16 (2000) 1014-1022
69. Jeffery C.J. Moonlighting proteins: old proteins learning new tricks. Trends Genet. Sci. 19 (2003) 415-417
70. Canete-Soler R., Reddy K.S., Tolan D.R., and Zhai J. Aldolases A and C are ribonucleolytic components of a neuronal complex that regulates the stability of the light-neurofilament mRNA. J. Neurosci. 25 (2005) 4353-4364
71. Sirover M.A. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim. Biophys. Acta. 1432 (1999) 159-184
72. Mazzola J., and Sirover M.A. Alteration of intracellular structure and function of glyceraldehyde-3-phosphate dehydrogenase: a common phenotype of neurodegenerative disorders?. Neurotoxicology 23 (2002) 603-609
73. Hod Y., Pentyala S.N., Whyard T.C., and El-Maghrabi M.R. Identification and characterization of a novel protein that regulates RNA-protein interaction. J. Cell. Biol. 72 (1999) 435-444
74. Lee S.J., Kim S.J., Ko J., Jeong C.S., et al. Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain. Proc. Nat. Acad. Sci. 100 (2003) 9256-9261
75. Taira T., Saito Y., Niki E., Iguchi-Ariga S.M., Takahashi K., and Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5 (2004) 213-218
76. Zhong N., Kim C.Y., Rizzu P., Geula C., Porter D.R., Pothos E.N.F., Squitieri F., Heuntik P., and Xu J. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J. Biol. Chem. 281 (2006) 20940-20948
77. Xu J., et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum. Mol. Genet. 14 (2005) 1231-1241
78. Bonifati V., Rizzo P., van Baren M.J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
79. Smythies J., and Galzigna L. The oxidative metabolism of catecholamines in the brain: a review. Biochim. Biophys. Acta 1380 (1998) 159-162
80. Wood-Kacmar A., Gandhi S., and Wood N.W. Understanding the molecular causes of Parkinson's disease. Trends in Mol. Med. 12 (2006) 521-528
81. Cookson M.R., Dauer W., Dawson T., Fon E.A., Guo M., and Shen J. The roles of kinases in familial Parkinson's disease. J. Neurosci. 27 (2007) 11865-11868
82. Thomas B., and Beal F.M. Parkinson's disease. Hum. Mol. Gen. 16 (2007) R183-R194